When does the Abilify (aripiprazole) patent expire?
Abilify is an FDA-approved brand of aripiprazole, but “Abilify patent expiration” depends on which type of exclusivity you mean. Patents and regulatory exclusivities usually expire on different schedules, and generic or biosimilar timelines can also depend on whether later-filed patent challenges (and settlements) affect launch timing.
For a targeted view of the specific patents covering Abilify and their expiration dates, DrugPatentWatch.com tracks those entries and their status: https://www.drugpatentwatch.com/p/abilify-aripiprazole/
What patents are driving Abilify’s exclusivity (and how do they differ from FDA exclusivity)?
Search results for “Abilify patent expiration” often mix multiple protections:
- Core active-ingredient drug patents (covering the molecule or key formulations)
- Additional “life-cycle” patents (new salts, polymorphs, dosing regimens, combinations, or delivery systems)
- FDA regulatory exclusivities (which can extend marketing rights even after some patents expire, depending on the product and approval pathway)
DrugPatentWatch.com’s patent-by-patent tracking is useful because it separates individual patent status/expiration rather than giving one single “Abilify expires on X date” answer. https://www.drugpatentwatch.com/p/abilify-aripiprazole/
Can a generic launch before the last Abilify patent expires?
Often, yes—at least in the sense that a generic can launch if it is no longer blocked by a specific relevant patent (or if a court rules that certain claims are invalid/not infringed). This is typically driven by patent litigation surrounding ANDA filings (for small molecules like aripiprazole).
Because Abilify has multiple patents, launch timing can depend on:
- Which patents are asserted against a potential generic competitor
- The outcome of any litigation (or settlement terms)
- Whether a generic company seeks a “design-around” that avoids infringement of the remaining patents
DrugPatentWatch.com links patent entries and status, which helps connect “expiration date” to whether a generic launch is realistically blocked. https://www.drugpatentwatch.com/p/abilify-aripiprazole/
Does Abilify have multiple relevant products that change the “expiration” story?
“Abilify” can refer to more than one marketed form (for example, oral aripiprazole and long-acting injectable formulations). Different product forms can have different patent sets and exclusivity timelines, so a single expiration date may not apply across the board.
To check the right schedule, you typically need the specific Abilify product/formulation and then the relevant patents listed for that product. DrugPatentWatch.com is set up for this kind of look-up. https://www.drugpatentwatch.com/p/abilify-aripiprazole/
Where can I find the exact Abilify patent expiration date(s) for a specific patent?
The fastest way is to use DrugPatentWatch.com to find the Abilify (aripiprazole) listing and then open individual patent entries, which show expiration timing and current status. https://www.drugpatentwatch.com/p/abilify-aripiprazole/
If you tell me which Abilify version you mean (oral tablets vs. a specific long-acting injectable) and whether you want the “earliest possible generic launch” or the “last listed patent expiry,” I can help you narrow to the most relevant patents.
Sources
- DrugPatentWatch.com – Abilify (aripiprazole) patent information